Related Experiment Video

Updated: Aug 16, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Final report on a placebo-controlled, double-blind, randomized, multicentre trial of cyclosporin treatment in active

J Brynskov1, L Freund, S Nørby Rasmussen

  • 1Dept. of Internal Medicine and Gastroenterology C, Herlev University Hospital, Copenhagen, Denmark.

Scandinavian Journal of Gastroenterology
|July 1, 1991
PubMed

Insights

Short-term cyclosporine treatment showed initial benefits for active Crohn's disease but did not lead to sustained long-term improvement in patients. Long-term outcomes for Crohn's disease patients were not significantly improved.

Area of Science:

  • Immunosuppressive therapy
  • Gastroenterology
  • Clinical trial research

Background:

  • Active chronic Crohn's disease requires effective therapeutic interventions.
  • Previous studies indicated short-term benefits of cyclosporine in Crohn's disease.
  • The long-term efficacy of cyclosporine in Crohn's disease remained to be fully elucidated.

Purpose of the Study:

  • To report the final outcome of patients with active chronic Crohn's disease treated with cyclosporine.
  • To evaluate the long-term therapeutic effect of cyclosporine beyond the initial treatment and tapering-off periods.
  • To assess the sustained impact of cyclosporine on Crohn's disease activity.

Main Methods:

  • A 3-month placebo-controlled trial followed by a tapering-off period was conducted.
  • Patients were assessed for clinical improvement and disease activity.
  • Statistical analysis was performed to determine the significance of cyclosporine treatment and interactions with prednisolone.

Main Results:

  • During the tapering-off period, a significant therapeutic gain for cyclosporine was observed (22-25%).
  • However, at final follow-up (6-month period), no significant differences were found between cyclosporine and placebo groups.
  • Only 19% of patients in the cyclosporine group showed substantial or moderate improvement at final follow-up.

Conclusions:

  • A short course of cyclosporine treatment does not yield long-term improvement in active chronic Crohn's disease.
  • The initial benefits of cyclosporine do not translate into sustained remission or significant long-term therapeutic gain.
  • Further research may be needed to explore alternative or combination therapies for long-term Crohn's disease management.

More Related Videos

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin10:21

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Published on: September 12, 2019

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

Related Concept Videos

Blinding01:11

Blinding

Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...